Comparative Pharmacology
Head-to-head clinical analysis: AMPYRA versus RUZURGI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPYRA versus RUZURGI.
AMPYRA vs RUZURGI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dalfampridine is a potassium channel blocker that improves conduction in demyelinated axons by prolonging action potential duration and increasing neurotransmitter release at synaptic junctions.
Amifampridine blocks voltage-gated potassium channels, thereby prolonging the action potential duration and increasing calcium influx at the nerve terminal. This enhances acetylcholine release at the neuromuscular junction, improving muscle strength.
10 mg orally twice daily (every 12 hours). Maximum 10 mg per dose.
32 mg orally three times daily (total daily dose 96 mg), to be taken with food.
None Documented
None Documented
Terminal elimination half-life approximately 5-7 hours. No clinically significant accumulation with twice-daily dosing.
Terminal elimination half-life is approximately 4.5 hours (range 3.5–5.5 h), supporting twice-daily dosing.
Primarily renal elimination via glomerular filtration and active tubular secretion. ~90% of administered dose excreted unchanged in urine. Fecal/biliary excretion negligible (<1%).
Primarily renal excretion of unchanged drug (~60%) with minor fecal elimination (~30%); <10% metabolized.
Category C
Category C
Potassium Channel Blocker
Potassium Channel Blocker